Johnson & Johnson Innovation Announces Collaborations with Two Canadian
Early-Stage Drug Technology Development Centers
MONTREAL & TORONTO -- December 10, 2013
Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada today
announced new collaborations with two Canadian early-stage drug technology
development centers, Montreal-based NEOMED and Toronto-based MaRS Innovation,
to identify and advance promising bio/pharmaceutical technologies that have
the potential to impact human health.
Through these collaborations, technical experts from the Johnson & Johnson
Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS
Innovation to identify investment opportunities emerging from well-validated
scientific research discoveries within their communities of academic
institutions and biotechnology companies.
“We know from our history of engagement that the Canadian bio/pharmaceutical
environment is one of the most vibrant in the world,” said Robert Urban, Head
of the Johnson & Johnson Innovation Center, Boston. “These new collaborations
will allow us to potentially advance important new clinical candidates against
“Quebec and Ontario are home to numerous world-class academic and biomedical
research enterprises,” said Paul Kershaw, Vice President of Medical Affairs,
Janssen Inc. in Canada. “These new relationships with NEOMED and MaRS
Innovation are an extension of our commitment to Canada’s innovative research
NEOMED is a not-for-profit, public-private Pharma alliance dedicated to drug
discovery and development. Partially funded by the Ministère des Finances et
de l’Économie du Québec, NEOMED is within the NEOMED Institute, a
state-of-the-art R&D facility in the Montréal Technoparc.
MaRS Innovationis the commercialization agent for Ontario’s discovery
pipeline from16 leading academic institutions. MaRS Innovation is supported
by the Government of Canada through theNetworks of Centres of Excellence, by
the Government of Ontario through theOntario Centres of Excellence, and by
its 16 member institutions.
About Johnson & Johnson Innovation
The Boston Innovation Center is part of Johnson & Johnson Innovation, a
division of Johnson & Johnson Finance Corporation. Johnson & Johnson
Innovation focuses on accelerating early innovation and enhancing
opportunities for collaboration and investment across Johnson & Johnson’s
global healthcare businesses. Johnson & Johnson Innovation provides
scientists, entrepreneurs and emerging companies focused on early-stage
opportunities a one-stop access to science and technology experts who can
facilitate collaborations across the pharmaceutical, medical device and
diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson
Innovation includes local deal-making capabilities with the flexibility to
adapt deal structures to match early-stage opportunities and establish novel
collaborations that speed development of those innovations to solve unmet
needs in patients. Follow us @jnjinnovation on Twitter. Please visit
www.jnjinnovation.com for more information.
About Janssen Inc.
Janssen is dedicated to addressing and solving some of the most important
unmet medical needs of our time in oncology, immunology, neuroscience,
infectious diseases and vaccines, metabolic and chronic diseases and women’s
health. Driven by our commitment to patients, we bring innovative products,
services and solutions to people throughout the world. Janssen Inc. in Canada
is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please
visit http://www.janssen.ca for more information.
Johnson & Johnson
John Lacey, 781-392-5514
Feinstein Kean Healthcare
Jessica Rowlands, 202-729-4089
Press spacebar to pause and continue. Press esc to stop.